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Summary.-Serum from rats bearing progressively growing aminoazo dye-induced
rat hepatomata has been fractionated by Sephadex G150gelfiltrationchromatography
and isolated fractions have been examined by indirect membrane immunofluores-
cence techniques to detect tumour specific antigen and antibody. HepatomaD23-
specific antigenic activity was associated with material (of approximate molecular
weight <150,000) isolated in the included volume of the gel at pH 7-3. The fraction
excluded from the gel (of approximate molecular weight >150,000) was adjusted
to pH 3-0 and further separated by Sephadex G150 gel filtration chromatography
at pH 3*0 into gel included and excluded fractions. Hepatoma D23 specific antibody,
demonstrable by membrane immunofluorescence staining ofhepatoma D23 cells, was
found to be eluted in the excluded volume and specific antigenic activity was retarded
into the included volume of the gel. These results indicate that hepatoma D23
bearer serum contains free circulating tumour specific antigen in excess, together
with specific immune complexes. The presence of these factors in tumour bearer
serum is discussed in terms of " blocking " phenomena whereby serum factors may
protect tumour cells from sensitized lymphocyte cytotoxic attack.
IT has been proposed that serum of
tumour bearing individuals contains fac-
tors which may interfere with the effective
mediation of cellular immunity (Hell-
strom and Hellstrom, 1969). Initially
this action was ascribed to " blocking
antibody" which protected cultured
tumour cells from cytotoxic attack by
sensitized lymphocytes. Fractionation of
Moloney sarcoma bearer serum by Sepha-
dex G200 gel filtration chromatography
(Hellstrom and Hellstr6m, 1969) and
aminoazo dye-induced rat hepatoma
bearer serum by either Sephadex G200
chromatography or sucrose density
gradient centrifugation (Baldwin, Price
and Robins, 1973d) indicated that block-
ing factors were associated with the 7s
immunoglobulin fraction. It was also
found that addition of heterologous anti-
mouse 78 immunoglobulin to Moloney
sarcoma bearer serum neutralized the
blocking activity. Several pieces of
evidence suggest that antibody alone may
not be the effective mediator of blocking
phenomena. For example, antibody was
not demonstrable in the serum of rats
bearing transplanted or primary hepa-
tomata, as assayed in serum cytotoxicity
tests (Baldwin, Embleton and Robins,
1973b). Furthermore, following surgical
excision of transplanted hepatomata,
blocking activity was rapidly lost (3-4
days) and concomitantly, complement-
dependent cytotoxic antibody became
detectable.
Evidence suggesting that the blocking
factor in tumour bearer serum was of
immune complexes has been obtained by
Sjogren et al. (1971, 1972). In studies
with Moloney virus-induced sarcomata
(Sjogren et al., 1971), the blocking factor
in tumour bearer serum was absorbed
onto viable tumour cells, eluted at pH 3 1
and fractionated by membrane ultra-
filtration into high and low molecular
weight fractions. These individually
lacked the capacity to block cell surfaceDETECTION OF CIRCULATING HEPATOMA D23 ANTIGEN
antigens when added to Moloney sarcoma
cells, but upon recombination tumour
cells were protected from lymphocytotoxic
attack. In this case, it was proposed
that the high and low molecular weight
fractions were antibody and antigen
respectively. Direct proof that tumour
specific antigen-antibody complexes can
interfere with lymphocyte-mediated cyto-
toxicity in vitro for cultured tumour cells
was obtained in studies with a trans-
planted rat hepatoma (Baldwin, Price and
Robins, 1972). Serum taken following
tumour excision was not blocking, al-
though contained complement-dependent
cytotoxic antibody. When appropriate
amounts of solubilized hepatoma D23
specific antigen were added, the serum
acquired the capacity to protect tumour
cells from sensitized lymphocyte attack.
A possible alternative mechanism for
blocking activity, which may be operative
in vivo, is that sensitized lymphocytes are
inhibited by their interaction with soluble
circulating antigen which may be present
in immune complexes or in a free form
(Cturrie and Basham, 1972; Baldwin,
Price an(l Robins, 1973d, e). In this
respect the cytotoxicity of sensitized
lymph node cells for cultured rat hepa-
toma cells can be inhibited by pretreating
lymphocytes with either hepatoma bearer
serum or solubilized hepatoma antigen
(Baldwin et al., 1973e). Similarly, it has
been established that solubilizedmembrane
antigen fro' carcinoma of the colon can
inhibit the cytotoxcity of patients' lym-
phocytes for cultured colon carcinoma cells
(Baldwin, Embleton and Price, 1973a).
The present studies were initiated with
a view to evaluating whether antigen,
both in immune complexes and in a free
form, could be identified positively in
the serum of rats bearing progressively
growing hepatomata.
MATERIALS AND METHODS
Rats and tumours. Hepatomata were
induced in Wistar rats of both sexes by oral
administration of 4-dimethylaminoazoben-
zene. Tumours were maintained by serial
subcutaneous passage in syngeneic recipients
of the same sex as the original host. Hepa-
tomata progressively growing in the peri-
toneal cavity of syngeneic rats were estab-
lished by intraperitoneal injection of chopped
tumour tissue suspended in phosphate buf-
fered saline, pH 7 3, containing 100 i.u./ml
of penicillin and 100 ,ug/ml of strepto-
mycin.
Hepatoma D23 tumour bearer serum.-
Groups of 30-40 rats bearing intraperitoneal
hepatoma D23 grafts were bled by cardiac
puncture under ether anaesthesia 9 days after
tumourimplantation and serum was collected.
The pooled serum was stored at -20TC
before fractionation.
Fractionation of hepatoma D23 tumour
bearer serum by salt precipitation and gel
filtration chromatography.-Saturated ammo-
nium sulphate solution (pH 6.4) was added
dropwise to hepatoma D23 tumour bearer
serum to give a final concentration of 3300
saturation. The precipitate was sedimented
by centrifugation at 600 g for 15 minutes and
the supernatant solutioncollectedanddialysed
against phosphate buffered saline, pH 7-3
(PBS) for 16 hours. The volume of the frac-
tion was adjusted to that of the original
seium by dialysis against Aquacide II (Calbio-
chemicals) and following further dialysis
against PBS for 16 hours, the fraction was
stored at -20°C before separation by gel
filtration.
Chromatographic columns (2-5 x 40 cm)
were packed with Sephadex G150 gel pre-
swollen in PBS containing 0-02%/ NaN3.
Aliquots of Blue Dextran 2000 (Pharmacia
Ltd.) solution in PBS were applied to the
columns which were then eluted by down-
ward flow (20 ml/hour) with PBS containing
0.02% NaN3. Following determination of
the void volume of the Sephadex G150
columns, aliquots (2-0 ml) of the supernatant
from ammonium sulphate treated hepatoma
D23 bearer serum were applied to the columns
and elution with PBS containing 0.02%
NaN3 was performed at a flow rate of 20 ml/
hour. Material eluted in the void volume
of the column (of approximate molecular
weight >150,000) was discarded and elution
was continued until the volume ofthe column
eluate was equivalent to 5 void volumes.
This fraction was concentrated by dialysis
against Aquacide II to a volume equivalent
to the original serum concentration, and
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dialysed against two changes of PBS for 16
hours before storing at -200C.
Fractionation of hepatoma D23 tumour
bearer serum by Sephadex G150 chromato-
graphy at pH 7-3 and pH 30O.-Aliquots
(2.0 ml) of hepatoma D23 tumour bearer
serum were fractionated by Sephadex G150
gel filtration chromatography at pH 7 3, as
described in the previous section. In these
tests, material eluted in the excluded volume
of the gel (approximate molecular weight
>150,000) and in the included volume of the
gel (approximate molecular weight <150,000)
were collected separately, concentrated by
dialysis against Aquacide II to 2-0 ml and
dialysed against PBS for 16 h.ours.
The fraction eluted in the excluded
volume ofthe Sephadex G150 gel.column was
further dialysed overnight against 60 mmol/l
citrate-phosphate buffer, pH 3 0, containing
0 02% NaN3. Aliquots (2.0 ml) were then
.applied to columns (2.5 x 40 cm) containing
Sephadex G150 pre-swollen in 60 mmol/l
citrate-phosphate buffer, pH 3 0 with 0 02%
NaN3 present, and elution was performed by
downward flow (20 ml/hour) with the same
buffer. The fraction eluted in the void
volume of the gel (determined by exclusion
of Blue Dextran, as described in the preced-
ing section) and the fraction eluted in the
included volume of the gel were adjusted to
pH 7 0 by addition of 1 mol/l NaOH. Both
fractions were concentrated to volumes
equivalent to the original serum by dialysis
against Aquacide II. Following dialysis
against two changes of PBS for 16 hours,
fractions were stored at -20°C.
All procedures in the, fractionation of
hepatoma D23 tumour bearer serum were
performed at 0-5°C and all further concen-
tration of serum fractions was carried out by
dialysis against Aquacide II followed by
dialysis against two changes of PBS for-16
hours.
Membrane immunofluorescence assay.-
The indirect menmbrane immunofluorescence
test was performed -with viable hepatoma D23
or D30 cells in suspension using sera from.rats
immunized by implantation of y-irradiated
(15,000 rad) tumour grafts (Baldwin and
Barker, 1967). Fluorescence indices were
calculated for test sera or serum fractions by
determining the percentage of cells unstained
with control normal rat serum minus the
percentage of cells unstained with test serum
divided by the former figure.
Antigen assay.-Soluble serum fractions
dialysed against PBS, were assayed for anti-
genic activity by determining their capacity
to neutralize the reaction of specific antibody
in hepatoma D23 immune serum with tumour
specific cell surface antigens on viable hepa-
tomaD23 cells as assessed usingthemembrane
immunofluorescence test (BaldwinandGlaves,
1972; Baldwin, Harris and Price, 1973c).
Antigenic activity associated with soluble
fractions was thus denoted by a reduction of
fluorescent staining with absorbed immune
serum as compared with immune serum
diluted with equivalent volumes of PBS.
Reductions ofthe fluorescence index to below
the value 0-30 were taken to represent a
significant neutralization of tumour-specific
antibody.
RESULTS
Demonstration of hepatoma D23 specific
antigen in serum of tumour bearing rats
Initial experiments were designed to
demonstrate the presence of soluble hepa-
toma D23 antigen in serum ofrats bearing
intraperitoneal growths of this tumour.
For this purpose serum was taken from
rats 9 days after intraperitoneal implan-
tation of tumour tissue, when tumours
(9-12 g) were well established and con-
tained little necrotic and haemorrhagic
tissue. At this stage no free tumour-
specific antibody was demonstrable in
serum by membrane immunofluorescence
staining of viable hepatoma D23 target
cells (fluorescence indices, Fl, 0 01-0-29).
Hepatoma D23 tumour bearer serum was
treated with ammonium sulphate to 33%
saturation under conditions which pre-
viously have been shown to precipitate
immune complexes with the crude y-
globulin fraction (Baldwin et al., 1973d).
The soluble supernatant fraction was then
separated by gel filtration chromato-
graphy on Sephadex G150. The gel
included and excluded fractions were
assayed for antigenic activity by deter-
miningtheir capacity toneutralizetumour-
specific antibody from syngeneic hepa-
toma D23 immune serum, this being
detected by a reduction of the serum
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TABLE 1.-Detection of Hepatoma D23-Speciftc Antigen in Hepatoma D23-Bearer
Serum
Serum
fraction*
Sephadex
G150, pH 7.3,
excluded
Sephadex
G150, pH 7.3,
included
Serum equivalent
concentration
x I
x I
x2
Antibody neutralizationi assayt
Unabsorbed Absorbed
serum Fl serum Fl
0-39 0-71
0-48 0-48
0-63 0-55
0-63 0-60
0-43 0-00
0-63 0-40
0-63 0-35
0-55 0-35
0-54 0-39
0-53 0-29
0-39 0-23
0-48 0-31
0-56 0-06
0-57 0-07
0-62 0-29
0-62 0-17
* Isolated by Sephadex G150 chromatography of the supernatant from hepatoma D23-bearer serum
treated with ammonium sulphate to 33% saturation.
t Antigen detected by the capacity of fractions to reduce the fluorescence index (FI) ofhepatoma D23-
immune rat serum with hepatoma D23 cells.
fluorescence index when tested against
viable hepatoma D23 target cells (Table
I). The fraction eluted in the excluded
volume of the gel failed to significantly
reduce the fluorescence index (FI) of the
standard immune serum so that the FI
(0-48-0-71) of the absorbed serum was
comparable with that determined for the
control unabsorbedhepatoma D23 immune
serum (0.39-0.63). However, upon assay-
ing the material isolated in the included
volume of the Sephadex G150 gel column,
in 3 tests out of 8, fractions at serum
equivalent concentration reduced the Fl
to below the level of 0-30 taken to repre-
sent significant membrane immunofluores-
cence staining (Table I). When Sephadex
G150 included fractions were concentrated
to an equivalent oftwo-fold concentration
in original serum, there was a significant
and reproducible neutralization of hepa-
toma D23 specific antibody in all tests.
No hepatoma D23 specific antibody was
demonstrable in the Sephadex G150
included fractions so that these fractions
failed to give significant immunofluores-
cence reactions when tested directly
against hepatoma D23 target cells at both
serum equivalent and two-fold serum
equivalent concentration (Fl, 0-06-0-11).
The presence ofhepatoma D23 antigen
in the Sephadex G150 included fraction
was further demonstrated by its capacity
to elicit hepatoma D23 specific humoral
antibody in syngeneic rats. In these
tests, a group of 4 rats were injected
intraperitoneally 3 times at weekly inter-
vals with the Sephadex G150 included
fraction so that each animal received a
total of 1-5 ml of the fraction at serum
equivalent concentration. Humoral anti-
body levels were determined 5 days after
the final immunization and -serum from
each of the immunized rats gave signifi-
cant membrane immunofluorescence re-
actions when tested against viable hepa-
toma D23 target cells (Fl, 0-31-0-64).
These results indicate that the serum of
rats bearing hepatoma D23 contain soluble
hepatoma D23 antigen which, under the
conditions used for antigen isolation, is
likely to be present in free form.
Chromatographic fractionation of whole
hepatoma D23- tumour bearer serum
More extensive studies were carried
out, using an alternative fractionation
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TABLE II.-Detection of Hepatoma D23-Specific Antigen and Antibody in Serum
from Hepatoma D23-Bearing Rat8
Antibody assay
Fluorescence index of
Hepatoma D23 Column
immune serum fraction
0.59 0*17
0 43 0 20
0-61
0-62
0*00
0-06
x5
Sephadex
G150, pH 3 0,
excluded
Sephadex
G150, pH 3 0,
included
x I
x2
x I
0*68
0*68
0*59
0*67
0 67
0 49
0*59
0*53
0*81
0*59
0*43
0-38
0 39
0 32
0-62
0*46
0-48
0.51
0*00
0*09
0-01
0*00
Antigen assay
Fluorescence index of
hepatoma D23-immune serum:
Absorbed
by column Percentage
Unabsorbed fraction reduction
0 54 0*29 46
0153 0-26 51
0*60 0-34 43
0-61 0 32 48
0-61 0*36 41
0*39 0 02 95
0-48 0*00 100
0*80 0 48 40
0 63 0*23 63
0-63 0-27 57
0-63 0-31 51
0*63 0*23 63
0 63 0*25 60
0-63 0-20 68
0*49 0*03 94
0-48 0*00 100
0-61 0*61 0
0-46 0*49 0
0-53 0-56 0
0*36 0 47 0
0 39
0-48
0-81
0*81
0*53
0 03
0*00
0 09
0-08
0 02
92
100
89
90
96
* A total of 10 fractionations at pH 7
-3 and 6 fractionations at pH 3 0 were performed. No fraction
from one preparation was tested more than twice in membrane immunofluorescence antigen and antibody
assays.
procedure, to evaluate whether both free
antigen and immune complexes could be
identified in the serum of hepatoma D23
bearing rats. Intheseexperiments, whole
serum was initially separated into the gel-
included and excluded fractions on Sepha-
dex G150 columns eluted with phos-
phate buffered saline, pH 7*3. As shown
in Table II, the material isolated in the
included volume of the columns and con-
centrated to the original serum equivalent
concentration, contained soluble hepa-
toma D23 antigen, as assayed by its
capacity toreduce the membrane immuno-
fluorescence staining of viable hepatoma
D23 cells by specific antibody in hepatoma
D23 immune serum. In these tests, the
percentage reduction ofthe serum FI after
absorption was between 40 and 100%,
although in only 4 tests was the FI of the
absorbed serum reduced to below the
value of030 taken to represent significant
membrane immunofluorescence staining.
When Sephadex G150 (pH 7.3) included
fractions were concentrated two- and
five-fold, however, they had the capacity
to effect significant and reproducible
neutralization of hepatoma D23 antibody
(Table II). Hepatoma D23 antigenic
activity in the Sephadex G150 (pH 7 3)
included fraction was also demonstrated
by its capacity to elicit hepatoma D23
specific humoral antibody in syngeneic
rats. A group of 4 rats received 3 intra-
peritoneal injections at weekly intervals
with 0 5 ml of the fraction at a concen-
tration equivalent to that in original
serum. Serum taken from immunized
Serum
fraction*
Sephadex
G150, pH 7 3,
included
Serum
equivalent
concentration
x I
x2
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rats 5 days after the final injection was
found to contain significant specific anti-
body demonstrable by membrane immuno-
fluorescence staining of hepatoma D23
cells (Fl, 0-36-0 51).
In order to detect immune complexes in
hepatoma D23 tumour bearer serum, the
fraction excluded from Sephadex G1 50
gel columns at pH 7-3 was adjusted to
pH 3 0 by overnight dialysis against
60 mmol/l citrate-phosphate buffer, pH 3 0.
This fraction was then separated by Sepha-
dex G150 gel filtration chromatography
at pH 3-0 into the gel-excluded and
included fractions. Following adjustment
to pH 7 0 and concentration to original
serum volume, both fractions were exam-
ined for hepatoma D23 specific antigen
and antibody content. Under the frac-
tionation conditions adopted, antigenic
activitv was associated with material
isolated in the included volume of the
column eluate, since these fractions
(Sephadex G150 pH 3 0 included) pro-
duced significant inhibition of membrane
immunofluorescence staining of hepatoma
D23 cells by specific antibody in hepatoma
D23 immune serum (percentage reduction
ofFI 89to 100%, Table II). Noantibody
was, however, demonstrable by direct
interaction of the extract with viable
hepatoma D23 cells (FJ, 0 00-0 09, Table
II). Conversely, the excluded fraction
was devoid of antibody-neutralizing
capacity, although it exhibited detect-
able levels of hepatoma D23 specific
antibody. Thus, positive membrane
immunofluorescence stainingwasdisplayed
by this fraction when tested against viable
hepatoma D23 cells (Fl, 0 32-0 62, Table
II).
The 3 fractions isolated from hepatoma
D23 tumour bearer serum by Sephadex
G1I50 column chromatography were exam-
inedforcross-reactivitywith hepatomaD30
cell surface-expressed antigen and specific
antibody in hepatoma D30 immune serum.
For this purpose, fractions were tested
both directly against viable hepatoma
D30 cells in membrane immunofluores-
cence assays and also for their capacity to
neutralize the membrane immunofloures-
cence staining of specific antibody in
hepatoma D30 immune serum with viable
hepatoma D30 cells (Table III). In
antibody assays, positive immunofluores-
cence reactions (Fl, 0-38-0.51) were
obtained with serum from hepatoma D30
immune rats tested against hepatoma
D30 cells, whereas serum from hepatoma
D23 immune rats showed no staining
with hepatoma D30 cells (Fl, 0.00-0-05)
(Table III). Similarly, all fractions iso-
lated by gel filtration chromatographic
TABLE III. Specificity Testsfor Hepatoma D23-Anitiyen and Antibody Isolated
from Hepatomna D23-Bearer Serum
Sertum
Serum equivalent,
fractionl concentration
x I
x 2
x 2
x I
Antibody assay
Fluorescence index with hepatoma
D30 cells of
l4epatoma D30
immune seruim
0- 38
0 -49
0 *47
0 38
0-38
O * 49
4) 51
Hepatoma D23
immuine seruim
() 03
o)03
U()30
0-3
(4-05
0 03
44. 443 405-0
(0(4 0
Colutmnl
fraction
(4 00
() .(4
()
4 00
004)
Hepatoma D30-antibody
neutralization
Fltuorescence index with
hepatoma D30 cells of
Unabsorbed Absorbed
hepatoma D30 hepatoma D3()
immune sertum immune serum
0 42 0*44
0-31 0 36
0-41 0- 40
0: 47 0-51
0 42 0- 44
0-31 0-38
(-41 0(40
0 47 0 449
0-42 0 47
(0- 31 0-46
0*41 ()-45
0 47 () 37
Sephadex
G1O0, pH 7 * 3,
included
Sephadex
G50O, pH 3(0,
excltided
Sephadex
Or50, pH 3 0,
included
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separation of hepatoma D23 tumour
bearer serum displayed no demonstrable
antibody reactivity towards hepatoma
D30 target cells (Fl, 0 00-0 06). In
addition, none of the serum fractions
isolated exhibited the capacity to neutra-
lize hepatoma D30 specific antibody since
the membrane immunofluorescence stain-
ing ofhepatoma D30 cells with unabsorbed
hepatoma D30 immune serum (Fl, 0-31-
0-47) was comparable with the reactions
obtained with immune serum absorbed
with hepatoma D23 bearer serum fractions
(Fl, 0 36-0 51) (Table III).
These results indicate that the serum
from hepatoma D23 bearing rats contains
soluble hepatoma D23 specific antigen
both in a free form and complexed with
hepatoma D23 specific antibody.
DISCUSSION
It has been proposed that the serum
from tumour-bearing individuals contains
both free circulating tumour-specific anti-
gen and immune complexes which may
interfere with the effective mediation of
cellular immunity (Sjogren et al., 1971,
1972; Currie and Basham, 1972; Baldwin
et al., 1973d, e; Thomson, Steele and
Alexander, 1973). Blocking of tumour
cells from attack by sensitized lympho-
cytes following tumour antigen " mask-
ing" at the cell surface by immune com-
plexes has been postulated on the basis
that the factor in tumour bearer serum
can be dissociated at low pH into two
components which individually lack acti-
vity (Sjogren et al., 1971). This is
supported by the finding that immune
complexes prepared by adding hepatoma
D23 solubilized antigen to tumour-specific
antibody can block hepatoma D23 cells
from cytotoxic lymphocytes (Baldwin et
al., 1972). Direct inhibition of lympho-
cyte cytotoxicity against hepatoma D23
cells has also been obtained by exposing
the effector cells to serum from tumour-
bearing rats (Baldwin et al., 1973e).
Furthermore, this effect is produced
following incubation of sensitized lympho-
cytes with solubilized hepatoma D23
antigen (Baldwin et al., 1973e) so that the
reactivity of tumour bearer serum is due
either to free antigen or immune com-
plexes. The alternative possibility that
lymphocyte inhibition by tumour bearer
serum is mediated by tumour specific
antibody cannot be supported, since no
such inhibitionwas observedwhenlympho-
cytes were treated with tumour immune
serum (Baldwin et al., 1973d, e). The
view that circulating tumour-specific anti-
gen, either free or bound to antibody, can
inhibit lymphocyte cytotoxicity directly
is supported by studies of Currie and
Basham (1972) on patients with advanced
metastatic melanoma. Peripheral lym-
phocytes from these patients exhibited
little or no cytotoxicity for melanoma
cells, but this activity developed following
extensive washing of the lymphocytes.
Moreover, lymphocytes were again inacti-
vated following incubation with melanoma
patients' serum.
More direct evidence that there are
free antigenic determinants in tumour
bearer serum has been obtained by Thom-
son et al. (1973) who demonstrated that
3-methylcholanthrene-induced rat sar-
coma bearer serum, insolubilized by cross-
linking with glutaraldehyde, had the
capacity to absorb tumour-specific anti-
body from immune serum. In this case,
it is possible that antibody absorption was
produced by free tumour antigen in
tumour bearer serum although it may be
that the antigen moiety of immune com-
plexes also effected absorption of specific
antibody.
In the present studies, free circulating
hepatoma D23 antigen and tumour specific
immune complexes have been positively
identified in the serum of rats bearing
progressively growing hepatoma D23
grafts. Although the nature of the anti-
gen in tumour bearer serum is largely
unknown, it is evident that the serum
antigen has a molecular weight less than
1150,000 since antigenic activity is retained
inthe included volume following chromato-
graphy on Sephadex G150. This findingDETECTION OF CIRCULATING HEPATOMA D23 ANTIGEN 23
is compatible with the results obtained
upon the fractionation of serum from
tumour bearing animals (Sj6gren et al.,
1971; Thomson et al., 1973) and cancer
patients (Sjogren et al., 1972) where the
molecular weight ofthe circulating tumour
antigen moiety was implied to be less than
100,000 in separations achieved by mem-
brane ultrafiltration.
Although free circulating hepatoma
D23 antigen was demonstrable in hepa-
toma-bearerserum inthe presentinvestiga-
tion, it was probable that the majority of
the antigen was associated with immune
complexes. Within the limits of the
membrane immunofluorescence assay for
tumour-specific antigen, itwas not possible
to determine precise levels of antigen in
serum. However, as shown in Table II,
in order to detect reproducibly significant
amounts oftumour antigen included in the
Sephadex G150 gel at pH 7 3, it was
necessary to test isolated fractions at
concentrations higher than those in the
original sera, whereas the antigen fraction
isolated at pH 3 0 from immune com-
plexes exhibited significant activity when
tested at serum-equivalent concentrations.
It is clear that these essentially qualita-
tive findings require further evaluation
using more quantitative methods for
detecting circulating tumour antigen and
immune complexes. It must also be
emphasized that these findings relate to a
particular stage in the growth ofhepatoma
D23 when implanted intraperitoneally.
Nevertheless, it is pertinent to consider
these serological findings with the immuno-
logical responses to tumour-specific rejec-
tion antigens demonstrable in rats bearing
established grafts ofhepatoma D23 (Bald-
win et al., 1973b). In this situation,
cytotoxic lymphocytes are detectable in
lymph nodes and the peripheral circula-
tion (Baldwin et at., 1973b; Baldwin and
Embleton, unpublished findings). In con-
trast, tumour-specific antibody is not
demonstrable either by membrane immu-
nofluorescence or serum cytotoxicity
assays. On the other hand, serum from
tumour-bearer rats specifically blocks
plated hepatoma D23 from attack by
sensitized lymphocytes (Baldwin et al.,
1973b) and this effect is most likely
mediated by tumour-specific immune com-
plexes comparable with the effects pro-
duced by mixtures of solubilized antigen
and hepatoma D23-antibody (Baldwin
etal., 1972). Hepatoma D23-bearerserum
also specifically inhibits cytotoxicity of
lymphocytes from tumour-immune rats
following short incubation of the effector
cells with serum. This effect may be
mediated by either free hepatoma D23
antigen or immune complexes (Baldwin
et al., 1973e) but the observation (Baldwin
and Robins, unpublished findings) that
reactivity is abrogated by the addition of
tumour-specific antibodyto tumour bearer
serum indicates the requirement for free
antigenic receptors.
In the tumour-bearing host a combina-
tion ofseveral factors may be operative in
determining the relative concentration of
free and complexed tumour antigen in the
circulation. This will include the height
of the tumour immune response, the rela-
tive contribution of cellular and humoral
reactions and the extent oftumour antigen
release governed by tumour cell turnover
(cellular proliferation and degeneration).
It is evident that the participation of
humoral factors in cellular immune re-
actions in the tumour-bearing host is of a
complex nature. The studies presented
here provide a basis for the further purifi-
cation and biochemical characterization
of the humoral factors occurring in res-
ponse to growing tumour which, in con-
junction with evaluation of the cellular
and humoral immune responses to tumour-
associated antigens, should provide a
critical assessment ofthe significant events
modifying tumour growth.
This work was supported by grants
from the Cancer Research Campaign and
the Medical Research Council.
REFERENCES
BALDWIN, R. W. & BARKER, C. R. (1967) Demon-
stration of Tumour-specific Humoral Antibody
against Aminoazo Dye-induced Rat Hepatomata.
Br. J. Cancer, 21, 793.24 R. W. BALDWIN, J. G. BOWEN AND M. R. PRICE
BALDWIN, R. W., EMBLETON, M. J. & PRICE, Al. R.
(1973a) Inhibition of Lymphocyte Cytotoxicity
for Human Colon Carcinoma by Treatment with
Solubilized Tumour Membrane Fractions. Int.
J. Cancer. In the press.
BALDWIN, R. W., EMBLETON, M. J. & ROBINS, R. A.
(1973b) Cellular and Humoral Immunity to Rat
Hepatoma-specific Antigens Correlated with
Tumour Status. Int. J. Cancer, 11, 1.
BALDWIN, R. W. & GLAVES, D. (1972) Solubilization
of Tumour-specific Antigen from Plasma Mem-
brane ofan Aminoazo Dye-induced Rat Hepatoma.
Clint. & Exp. Inmnunol., 11, 51.
BALDWIN, R. W., HARRIS, J. R. & PRICE, M. R.
(1973c) Fractionation of Plasma Membrane-
associated Tumour Specific Antigen from an
Aminoazo Dye-induced Rat Hepatoma. Int. J.
Cancer, 11, 385.
BALDWIN, R. W., PRICE, M. R. & ROBINS, R. A.
(1972) Blocking of Lymphocyte-mediated Cyto-
toxicity for Rat Hepatoma Cells by Tumour-
specific Antigen-Antibody Complexes. Nature,
iNew Biol., 238, 185.
BALDWIN, R. W., PRICE, M. R. & ROBINS, R. A.
(1973d) Characterization of Serum Factors
Blocking Lymphocyte Cytotoxicity for Tumor
Cells. In Imnmunological Aspects of Neoplasia.
The University of Texas M.D. Anderson Hospital
and Tumor Institute at Houston, 26th Annual
Symposium on Fundamental Cancer Research,
Baltimore, Maryland. In the press.
BALDWIN, R. W., PRICE, M. R. & ROBINS, R. A.
(1973e) Inhibition of Hepatoma Immune Lymph
Node Cell Cytotoxicity by Tumour Bearer Serum,
and Solubilized Hepatoma Antigen. Int. J.
Cancer. In the press.
CURRIE, G. A. & BASHAM, C. (1972) Serum AMediated
Inhibition of the Immunological Reactions of the
Patient to His Own Tumour: A Possible Role for
Circulating Antigen. Br. J. Cancer, 26, 427.
HELLSTROM, I. & HELLSTR6M, K. E. (1969) Studies
on Cellular Immunity and Its Serum-mediated
Inhibition in Moloney-virus-induced Mouse Sar-
comas. Int. J.. Cancer, 4, 587.
SJOGREN, H. O., HELLSTROM, I., BANSAL, S. C. &
HELLSTROM, K. E. (1971) Suggestive Evidence
that the " Blocking Antibodies" of Tumor
Bearing Individuals may be Antigen-Antibody
Complexes. Proc. natn. Acad. Sci. U.S.A., 68,
1372.
SJOGREN, H. O., HELLSTROM, I., BANSAL, S. C.,
WARNER, G. A. & HELLSTROM, K. E. (1972)
Elution of '"Blocking Factors" from Human
Tumors, Capable of Abrogating Tumor Cell
Destruction by Specifically Immune Lymphocytes.
Int. J. Cancer, 9, 274.
THOMSON, D. M. P., STEELE, K. & ALEXANDER, P.
(1973) The Presence of Tumour-specific Membrane
Antigen in the Serum of Rats with Chemically
Induced Sarcomata. Br. J. Cancer, 27, 27.